← Evidence map

ArticleFrontiers in oncology2026

LASSO-based nomogram to predict early treatment failure in advanced hepatocellular carcinoma treated with SBRT, lenvatinib, and tislelizumab.

Yingchun Zhao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

LASSO-based nomogram to predict early treatment failure in advanced hepatocellular carcinoma treated with SBRT, lenvatinib, and tislelizumab. | OpenQuestion